Abstract
The caspase-mediated cleavage of a limited number of cellular proteins is a common feature of apoptotic cell death. This cleavage usually inhibits the function of the target protein or generates peptides that actively contribute to the death process. In the present study, we demonstrate that the cyclin-dependent kinase inhibitor p27Kip1 is cleaved by caspases in human leukemic cells exposed to apoptotic stimuli. We have shown recently that p27Kip1 overexpression delayed leukemic cell death in response to cytotoxic drugs. In transient transfection experiments, the p23 and the p15 N-terminal peptides generated by p27Kip1 proteolysis demonstrate an anti-apoptotic effect similar to that induced by the wild-type protein, whereas cleavage-resistant mutants have lost their protective effect. Moreover, stable transfection of a cleavage-resistant mutant of p27Kip1 sensitizes leukemic cells to drug-induced cell death. Altogether, these results indicate that proteolysis of p27Kip1 triggered by caspases mediates the anti-apoptotic activity of the protein.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barik S. . 1993 Meth. Mol. Biol. 15: 277–286.
Beyaert R, Kidd VJ, Cornelis S, VandeCraen M, Denecker G, Lahti JM, Gururajan R, Vandernabeele P and Fiers W. . 1997 J. Biol. Chem. 272: 11694–11697.
Boise LH and Thompson CB. . 1997 Proc. Natl. Acad. Sci. USA 94: 3759–3764.
Cardone MH, Salvesen GS, Widmann C, Johnson G and Frisch SM. . 1997 Cell 90: 315–323.
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM. . 1997 Nature Med. 3: 227–230.
Cock JG, de Vries E, Williams GT and Borst J. . 1998 Apoptosis 3: 17–25.
Dimanche-Boitrel MT, Micheau O, Hamman A, Haugg M, Eymin B, Chauffert B and Solary E. . 1998 Int. J. Cancer 77: 796–802.
Dubrez L, Goldwasser F, Genne P, Pommier Y and Solary E. . 1995 Leukemia 9: 1013–1024.
Dubrez L, Savoy I, Hamman A and Solary E. . 1996 EMBO J. 15: 5504–5512.
Eymin B, Haugg M, Droin N, Sordet O, Dimanche-Boitrel MT and Solary E. . 1999 Oncogene 18: 1411–1418.
Fearnhead HO, Dinsdale D and Cohen G. . 1995 FEBS Lett. 375: 283–288.
Fero ML, Rivkin M, Tash M, Porter P, Carow CE, Firpo E, Polyak K, Tsai L, Broudy V, Perlmutter RM, Kaushansky K and Roberts JM. . 1996 Cell 85: 733–744.
Hentgartner MO. . 1998 Nature 391: 441–442.
Janicke RU, Walker PA, Lin XY and Porter AG. . 1996 EMBO J. 15: 6969–6978.
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG. . 1993 Cancer Res. 53: 3976–3985.
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Lee YY, Bartram CR and Koeffler HP. . 1995 Cancer Res. 55: 2266–2269.
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A. . 1996 Cell 85: 721–732.
Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD and Kornbluth S. . 1998 J. Biol. Chem. 273: 16589–16594.
Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orht K, Roberts JM and Ross R. . 1998 Molecular Cell 1: 553–563.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X. . 1997 Cell 91: 479–489.
Liu X, Zou H, Slaughter C and Wang X. . 1997 Cell 89: 175–184.
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M. . 1997 Nature Med. 3: 231–234.
Mai A, Poon RYC, Howe PH, Toyoshima H, Hunter T and Harter LM. . 1996 Nature 380: 262–265.
Miossec C, Dutilleul V, Fassy F and Diu-Hercend A. . 1997 J. Biol. Chem. 272: 13459–13462.
Micheau O, Solary E, Hammann A and Dimanche Boitrel MT. . 1999 J. Biol. Chem. 274: 7987–7992.
Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K and Akiyoshi, T. . 1997 Nature Med. 3: 593.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY and Nakayama K. . 1996 Cell 85: 707–720.
Ophascharoensuk V, Fero ML, Hughes J, Roberts JM and Shankland SJ. . 1998 Nature Med. 4: 575–580.
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M. . 1995 Science 269: 682–685.
Patel T, Gores G and Kaufmann SH. . 1996 FASEB J. 10: 587–597.
Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massagué J. . 1994 Cell 78: 59–66.
Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS and Pickup DJ. . 1992 Cell 69: 597–604.
Roy N, Deveraux QL, Takahashi R, Salvesen, GS and Reed JC. . 1997 EMBO J. 16: 6914–6925.
Rudel T and Bokoch GM. . 1997 Science 276: 1571–1574.
Sherr JC. . 1996 Science 274: 1672–1677.
Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW and Cohen GM. . 1996 Biochem. J. 315: 21–24.
Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ. . 1999 J. Cell Biol. 25: 281–292.
Solary E, Bertrand R, Kohn KW and Pommier Y. . 1993 Blood 81: 1359–1368.
Susin SA, Lorenzo HK, Zamzami N, Marzo I, Brenner C, Larochette N, Prevost MC, Alzari PM and Kroemer G. . 1999 J. Exp. Med. 18: 381–394.
St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharaya N, Slingerland JM and Kerbel RS. . 1996 Nature Med. 2: 1204–1210.
Thorberry NA and Lazebnik Y. . 1998 Science 281: 1312–1316.
Tsihlias J, Kapusta LR, DeBoer G, Morava-Proztner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH and Slingerland JM. . 1998 Cancer Res. 58: 542–548.
Van de Craen M, Vandenabeele P, Declercq W, Van den brande I, Van Loo G, Molemans F, Schotte P, Van Criekinge W, Beyaert R and Fiers W. . 1997 FEBS Lett. 403: 61–69.
Vlach J, Hennecke S and Amati B. . 1997 EMBO J. 16: 5334–5344.
Wilhelm S, Wagner H and Hbcker G. . 1998 Euro. J. Immunol. 28: 891–900.
Xue D and Horwitz HR. . 1995 Nature 377: 248–251.
Acknowledgements
This work was supported by grants from INSERM, the Burgundy, Saône et Loire and Nievre Comitees of the Ligue Nationale Contre le Cancer and the Conseil Régional de Bourgogne. B Eymin was supported by CHU Le Bocage, Dijon.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eymin, B., Sordet, O., Droin, N. et al. Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. Oncogene 18, 4839–4847 (1999). https://doi.org/10.1038/sj.onc.1202860
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202860
Keywords
This article is cited by
-
p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma
Scientific Reports (2019)
-
Caspase-8-dependent control of NK- and T cell responses during cytomegalovirus infection
Medical Microbiology and Immunology (2019)
-
Caspases uncouple p27Kip1 from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasion
Oncogene (2016)
-
A caspase-dependent cleavage of CDC25A generates an active fragment activating cyclin-dependent kinase 2 during apoptosis
Cell Death & Differentiation (2009)
-
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
Oncogene (2008)
